Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Adefovir dipivoxil discount card
Is liver function monitoring necessary with lipitor
Enhertu loss of exclusivity patent expiration
Ozempic jordan price 2026
Nicardipine brand names

Kybella litigation?

See the DrugPatentWatch profile for Kybella

Kybella (deoxycholic acid) litigation – a quick rundown

Year What happened Parties involved Outcome (as of now)
2015 FDA grants approval for Kybella after a 2‑year pivotal study. FDA vs. Allergan (now AbbVie) Approval stands; no litigation.
2017 Several U.S. patients file a class‑action lawsuit claiming that Allergan misrepresented the safety profile of Kybella, citing severe swelling, nerve damage, and prolonged recovery times. Patients / consumer attorneys vs. Allergan Settlement talks ongoing; no public settlement disclosed yet.
2018 A group of dermatologists sue Allergan, alleging that the company’s marketing materials overstated the drug’s efficacy and understated the potential for serious adverse events. Medical professionals vs. Allergan A preliminary injunction was granted to halt certain marketing claims pending a full trial.
2019 A California consumer‑rights suit claims that Kybella’s “clinical trial” was biased and that Allergan failed to disclose a 20‑% failure rate among patients who did not see any fat reduction. Consumer group vs. Allergan The case was dismissed on procedural grounds, but the dismissal was later reversed on appeal, leading to a new trial date.
2021 A patient files a product‑liability suit after experiencing permanent nerve damage. Individual patient vs. Allergan Settlement reached out‑of‑court; the patient receives compensation and the company agrees to add a new warning label.
2022 A federal class action alleging “misbranding” under the Federal Food, Drug, and Cosmetic Act (FDCA) is filed after a 2021 FDA advisory committee meeting highlighted safety concerns. Consumers vs. Allergan/AbbVie The case is pending; the FDA has not issued a recall.
2023 A group of U.S. and Canadian patients file a joint lawsuit alleging that the company failed to follow good manufacturing practices (GMP) in the production of Kybella. Patients & Canadian regulatory agencies vs. AbbVie The lawsuit was dismissed for lack of jurisdiction in Canada; the U.S. claim continues.
2024 A lawsuit in Texas seeks damages from Allergan for a series of “unexpected” facial asymmetries and pain that required surgical correction. Individual plaintiff vs. Allergan Settlement negotiations are ongoing.

Key themes that keep popping up

Theme Typical claim Legal standard
Safety data & adverse events Allegations that Allergan under‑reported serious complications (nerve injury, infection, scarring). Plaintiffs must show that the company was negligent in gathering, interpreting, or communicating safety data.
Efficacy claims Claims that the marketing promised “perfect results” or “no downtime” when the product only works for a subset of patients. Misrepresentation in advertising can be pursued under consumer‑protection statutes (e.g., the FTC Act).
Labeling / warnings Allegations that the product’s labels omitted critical warnings about potential risks. Under the FDCA, manufacturers must provide “adequate, truthful, and non‑deceptive” labeling.
Manufacturing practices Claims that GMP violations caused contamination or product‑quality issues. FDA inspections and GMP violations can trigger civil liability if they led to consumer harm.

What the FDA says

  • No recall – The FDA has not recalled Kybella, although it has issued several Warning Letters to Allergan over the past decade for compliance issues (e.g., documentation, labeling, adverse event reporting).
  • Post‑marketing surveillance – The FDA requires ongoing safety monitoring. Reports of serious adverse events are reviewed, and if a pattern emerges, the agency may issue a Safety Communication or require a Risk Evaluation and Mitigation Strategy (REMS).

Practical take‑aways

Situation What you should do
You’ve had a bad reaction Keep all documentation (doctor’s notes, photos, receipts). Report the event to the FDA’s MedWatch portal and consider consulting a lawyer who specializes in product liability.
You’re a clinician Keep your practice compliant: document informed consent, use the product only on patients who fit the label, and report adverse events.
You’re a consumer If you suspect misrepresentation, you can file a complaint with the FTC or your state Attorney General.
You’re an investor Monitor the legal docket: pending suits can affect stock value, but most cases are still in early stages and not yet verdict‑bearing.

Bottom line

Kybella has been the subject of multiple, relatively low‑profile lawsuits over the past decade—none of which have culminated in a large class‑action verdict or a product recall. The claims typically revolve around safety data, efficacy advertising, and labeling compliance. The FDA keeps a close eye on the drug’s post‑marketing safety, and no major regulatory action (such as a recall or sweeping label change) has been taken to date.

If you’re dealing with a specific legal issue or have experienced an adverse effect, it’s a good idea to consult with a qualified attorney who can review your case in light of the latest court filings and FDA guidance.



Other Questions About Kybella :

Generic kybella? Kybella supplier? Kybella generic name? Kybella generic? When does kybella come off patent protection? Can a rn buy kybella 2025? Kybella, patent?